Soccer Fans, Don’t Root for a Team Based on Genetics
Editor's Note: This op/ed is in response to our Big Question of the month: "Should shared genetics play any role in encouraging sports fans to root for a certain team?"
23andMe is taking a lot of heat as one of the DNA aggregators whose databases may not be secure from prying third-party eyes. That is a huge issue, but the company is engaging in even more troubling behavior—using genetics to sponsor racism.
The ad campaign urges that you choose to root for a team based on genetics—theirs and yours.
There is plenty to condemn when it comes to racism in international sports. Fans taunting black and minority athletes is a huge problem. No sport has been as beset by racial taunting as soccer. Which is why the current advertising campaign by the genetic testing company 23andMe and Fox sports is especially foul.
With the U.S. men's team eliminated from the 2018 FIFA World Cup in Russia, many potential American fans were left without a primary rooting interest in the upcoming summer tournament. And that would be a disaster for Fox, which will be carrying the games.
The network teamed up with 23andMe to urge American soccer fans not to tune out the World Cup. Instead the ad campaign urges that you choose to root for a team based on genetics—theirs and yours. Given the fact that ethnicity and race are mainly cultural and social constructs, not biological, this suggestion seems more 19th than 21st century in terms of its justification.
The ads say, "root for your roots." Send your spit off to 23andMe for a DNA test and you might discover most of your genes came from one of the countries that did qualify for the biggest event in soccer. Saudi Arabia, for example. Or Panama, Argentina, Serbia, Senegal or Iran. So if you and the team have the same genes - voila, you have someone and something to root for. Soccer hooligan bigots everywhere must be thrilled by this twaddle.
There is no correlation between genetics and who is a member of a nation's soccer team. People from many ethnic and racial backgrounds play for many nations. There is no Argentinian or Croatian team genotype. And why would information about your genetic ancestry lead you to root for a particular athlete or team? How about the team's skill, not their skin color or biological makeup?
What genetic difference is it that we are going to root for anyway—the immune system differences between Switzerland and Egypt?
And are there really genes to be found that determine with certainty that you or the team you are watching are really Panamanian? Hardly. Panama is a political entity that came into existence in 1903 not a biological species. And, do we really need an ad campaign telling us, falsely, that the nations of the Earth can be sorted out neatly into clear racial groups based on their heredity? What genetic difference is it that we are going to root for anyway—the immune system differences between Switzerland and Egypt? Markers for bone density between Argentinians and Russians?
The 'root for your roots' campaign comes at a horrible time, just when FIFA is trying to root the racism out of the World Cup. It is built on bogus science about the genetics of how we define nations and ethnic groups. It appeals to the racism in us to pick a team we can root for. And it reinforces racial and ethnic stereotypes about human behavior and nationhood that are rooted in history, culture, economics, colonialism and prejudice, not ancestry, genetics or biology. This is not the way to introduce the world to genetic testing.
[Ed. Note: To read the counter viewpoint, click here. Then visit leapsmag on social media to share your opinion: Who wins this debate?]
When a patient is diagnosed with early-stage breast cancer, having surgery to remove the tumor is considered the standard of care. But what happens when a patient can’t have surgery?
Whether it’s due to high blood pressure, advanced age, heart issues, or other reasons, some breast cancer patients don’t qualify for a lumpectomy—one of the most common treatment options for early-stage breast cancer. A lumpectomy surgically removes the tumor while keeping the patient’s breast intact, while a mastectomy removes the entire breast and nearby lymph nodes.
Fortunately, a new technique called cryoablation is now available for breast cancer patients who either aren’t candidates for surgery or don’t feel comfortable undergoing a surgical procedure. With cryoablation, doctors use an ultrasound or CT scan to locate any tumors inside the patient’s breast. They then insert small, needle-like probes into the patient's breast which create an “ice ball” that surrounds the tumor and kills the cancer cells.
Cryoablation has been used for decades to treat cancers of the kidneys and liver—but only in the past few years have doctors been able to use the procedure to treat breast cancer patients. And while clinical trials have shown that cryoablation works for tumors smaller than 1.5 centimeters, a recent clinical trial at Memorial Sloan Kettering Cancer Center in New York has shown that it can work for larger tumors, too.
In this study, doctors performed cryoablation on patients whose tumors were, on average, 2.5 centimeters. The cryoablation procedure lasted for about 30 minutes, and patients were able to go home on the same day following treatment. Doctors then followed up with the patients after 16 months. In the follow-up, doctors found the recurrence rate for tumors after using cryoablation was only 10 percent.
For patients who don’t qualify for surgery, radiation and hormonal therapy is typically used to treat tumors. However, said Yolanda Brice, M.D., an interventional radiologist at Memorial Sloan Kettering Cancer Center, “when treated with only radiation and hormonal therapy, the tumors will eventually return.” Cryotherapy, Brice said, could be a more effective way to treat cancer for patients who can’t have surgery.
“The fact that we only saw a 10 percent recurrence rate in our study is incredibly promising,” she said.
Few things are more painful than a urinary tract infection (UTI). Common in men and women, these infections account for more than 8 million trips to the doctor each year and can cause an array of uncomfortable symptoms, from a burning feeling during urination to fever, vomiting, and chills. For an unlucky few, UTIs can be chronic—meaning that, despite treatment, they just keep coming back.
But new research, presented at the European Association of Urology (EAU) Congress in Paris this week, brings some hope to people who suffer from UTIs.
Clinicians from the Royal Berkshire Hospital presented the results of a long-term, nine-year clinical trial where 89 men and women who suffered from recurrent UTIs were given an oral vaccine called MV140, designed to prevent the infections. Every day for three months, the participants were given two sprays of the vaccine (flavored to taste like pineapple) and then followed over the course of nine years. Clinicians analyzed medical records and asked the study participants about symptoms to check whether any experienced UTIs or had any adverse reactions from taking the vaccine.
The results showed that across nine years, 48 of the participants (about 54%) remained completely infection-free. On average, the study participants remained infection free for 54.7 months—four and a half years.
“While we need to be pragmatic, this vaccine is a potential breakthrough in preventing UTIs and could offer a safe and effective alternative to conventional treatments,” said Gernot Bonita, Professor of Urology at the Alta Bro Medical Centre for Urology in Switzerland, who is also the EAU Chairman of Guidelines on Urological Infections.
The news comes as a relief not only for people who suffer chronic UTIs, but also to doctors who have seen an uptick in antibiotic-resistant UTIs in the past several years. Because UTIs usually require antibiotics, patients run the risk of developing a resistance to the antibiotics, making infections more difficult to treat. A preventative vaccine could mean less infections, less antibiotics, and less drug resistance overall.
“Many of our participants told us that having the vaccine restored their quality of life,” said Dr. Bob Yang, Consultant Urologist at the Royal Berkshire NHS Foundation Trust, who helped lead the research. “While we’re yet to look at the effect of this vaccine in different patient groups, this follow-up data suggests it could be a game-changer for UTI prevention if it’s offered widely, reducing the need for antibiotic treatments.”